Hip Fractures (ICD-10 72.01-72.2)NCT07301242
Population Pharmacokinetics and Pharmacodynamics of Ciprofol
An observational study of Hip Fractures (ICD-10 72.01-72.2) and Osteoarthritis, Knee and Hip, run by Shanghai Geriatric Medical Center at 1 site in China.
Trial summary
The goal of this observational study is to learn how the anesthetic drug ciprofol works in older adults who are having limb surgery under general anesthesia at Shanghai Geriatric Medical Center. Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Hip Fractures (ICD-10 72.01-72.2), Osteoarthritis, Knee and Hip, Femoral Neck Fractures
- What is being tested?
- Ciprofol
- Type of treatment
- Injection or infusion
- How many people
- 50 participants
- Where
- 1 siteChina
- Study dates
- 28 Oct 2025to Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Study population: Elderly patients undergoing orthopedic limb surgery
Who may be able to join
- Age ≥65 years;
- BMI: 18-30 kg/m²;
- ASA physical status classification I-III;
- Scheduled for elective orthopedic limb surgery under general anesthesia;
- Expected duration of surgery >30 minutes;
- Willing to participate and able to provide written informed consent.
Who cannot join
- Known allergy to ciprofol or related medications, or any contraindication to their use;
- Preoperative cognitive impairment;
- History of severe cerebrovascular disease or related complications;
- History of neuromuscular system diseases or psychiatric disorders;
- History of sedative medication use;
- History of alcohol abuse or substance use disorder;
Show all 10Show fewer
- Bradycardia (heart rate <60 beats per minute);
- Hypotension (mean arterial pressure <55 mmHg);
- QT interval prolongation;
- Uncooperative or unable to communicate effectively.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Shanghai Geriatric Medical Center
Shanghai
Clinical Research Coordinator, 021-64175590, zx02190554@126.com
About this study
Official title: Population Pharmacokinetic/Pharmacodynamic Modeling of Ciprofol in Elderly Patients Undergoing Orthopedic Limb Surgery
The goal of this observational study is to learn how the anesthetic drug ciprofol works in older adults who are having limb surgery under general anesthesia at Shanghai Geriatric Medical Center. The study will help researchers build a population model to better understand how the drug moves through the body (PK) and how it affects patients (PD). This model may help doctors use a Target-Controlled Infusion (TCI) system to adjust the drug dose more precisely.
The main question it aims to answer is: Does ciprofol work safely and effectively in older adults during orthopedic surgery?
Read more
Participants already receiving ciprofol as part of their regular anesthesia care will:
- Provide blood samples at different time points during and after surgery.
- Have their vital signs and anesthesia-related data recorded before, during, and after surgery.
- Be monitored for side effects and recovery indicators such as the Aldrete score and signs of postoperative delirium.
Researchers will use this information to:
- Build and test a population PK/PD model for ciprofol.
- Simulate recommended TCI dosing plans.
- Explore how individual responses to ciprofol relate to recovery and safety outcomes.
This study may help improve anesthesia care for elder adults by making drug dosing safer and more effective.
Read the detailed description
Elderly patients undergoing orthopedic limb surgery represent a growing population with unique perioperative challenges. Age-related physiological changes-including reduced hepatic and renal function, altered body composition, and decreased cardiac output-significantly affect the pharmacokinetics (PK) and pharmacodynamics (PD) of anesthetic drugs. These changes increase the difficulty of maintaining adequate anesthesia depth and hemodynamic stability.
Ciprofol, a novel intravenous anesthetic, has shown promising efficacy and safety in clinical practice. However, existing PK/PD models are largely derived from healthy volunteers or younger patients, and cannot adequately predict drug behavior in elderly orthopedic patients who often present with comorbidities and heightened surgical stress. This gap may lead to risks such as drug accumulation and circulatory depression, or insufficient dosing and intraoperative awareness.
This single-center, observational, prospective study at Shanghai Geriatric Medical Center aims to construct and validate a population PK/PD model of ciprofol specifically for elderly patients undergoing orthopedic limb surgery. The model will support precise control of effect-site concentration via Target-Controlled Infusion (TCI) systems, enabling individualized anesthesia management.
Study Objectives 1.Primary Objective: To develop and validate a population PK/PD model of ciprofol tailored to elderly orthopedic patients, and to evaluate its accuracy in predicting effect-site concentrations.
2.Secondary Objectives:
- To simulate recommended TCI dosing regimens based on the new model and compare them with current drug label recommendations, assessing clinical value and optimization potential.
- To evaluate the anesthetic efficacy and safety of ciprofol in this patient population.
3.Exploratory Objectives: To investigate the influence of covariates (e.g., age, sex, BMI, hepatic and renal function) on PK/PD parameters, and to explore correlations between individual PK/PD parameters and recovery outcomes such as Aldrete score and postoperative delirium incidence.
Study Design
1.Type: Single-center, observational, biosample-utilization study. 2.Population: 45 elderly patients (≥65 years, ASA I-III) scheduled for elective orthopedic limb surgery under general anesthesia.
3.Procedures:
- Collection of perioperative clinical data (vital signs, BIS monitoring, anesthesia-related indicators).
- Serial blood sampling at predefined time points for plasma concentration measurement.
- Monitoring of anesthetic efficacy (induction success, BIS values, recovery times) and safety endpoints (hypotension, bradycardia, hypoxemia, injection pain).
4.Endpoints:
- Primary Endpoint: Accuracy of the population PK/PD model in predicting effect-site concentrations.
- Secondary Endpoints: Differences between model-recommended dosing and label-based dosing; incidence of ciprofol-related adverse events; anesthetic efficacy indicators.
- Exploratory Endpoints: Covariate effects on PK/PD parameters; correlation of PK/PD parameters with Aldrete score recovery and postoperative delirium.
Data Management and Analysis All perioperative data will be recorded and stored electronically, with double-entry verification and query resolution procedures to ensure accuracy. PK/PD modeling will be performed using nonlinear mixed-effects modeling (NONMEM). Model evaluation will include goodness-of-fit plots, visual predictive checks, and bootstrap validation. Simulations will be conducted to compare TCI dosing regimens derived from the new model with standard recommendations.
Expected Significance This study will fill an important gap in anesthetic pharmacology by providing a validated PK/PD model of ciprofol for elderly orthopedic patients. The findings are expected to improve perioperative anesthesia management, enhance patient safety, and support individualized dosing strategies in clinical practice.
- Being tested
- Ciprofol
- Medical subject headings
- Hip Fractures, Osteoarthritis, Femoral Neck Fractures
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CiprofolDrug
Also called Cipepofol, Sishuning
Ciprofol is used as an intravenous anesthetic agent for sedation and anesthesia induction/maintenance in elderly patients undergoing elective orthopedic limb surgery. In this observational study, ciprofol is administered according to standard clinical practices, and data on its pharmacokinetics, pharmacodynamics, safety, and effectiveness in this specific population will be collected.
| Study group | Role | What they receive |
|---|---|---|
| Elderly Orthopedic Limb Surgery Cohort | Inclusion Criteria:
Age ≥65 years; BMI 18-30 kg/m²; ASA physical status classification I-III; Scheduled for elective orthopedic limb surgery under general anesthesia; Expected duration of surgery >30 minutes; Willing to participate and able to provide written informed consent.
Exclusion Criteria:
Known allergy to ciprofol or related medications, or any contraindication to their use; Preoperative cognitive impairment (Mini-Cog score <3); History of severe cerebrovascular disease or related complications; History of neuromuscular system diseases or psychiatric disorders; History of sedative medication use; History of alcohol abuse or substance use disorder; Bradycardia (heart rate <60 beats per minute); Hypotension (mean arterial pressure <55 mmHg); QT interval prolongation; Uncooperative or unable to communicate effectively. Receives: Drug: Ciprofol |
What is being measured
The primary outcome is the main question the study is designed to answer.
Plasma Concentration of Ciprofol
Arterial or venous blood samples (1 mL each) will be collected to measure the plasma concentration of ciprofol using liquid chromatography - mass spectrometry. These concentration data points will be used to construct the population pharmacokinetic model. Reported in ng/mL.
Measured: From the start of drug administration to 24 hours after the end of drug administration.
Bispectral Index (BIS) Value
The BIS value is a non-invasive measure of the level of consciousness/depth of anesthesia, ranging from 0 (isoelectric EEG) to 100 (awake). It is used as the pharmacodynamic metric for modeling.
Measured: Continuously monitored from the start of anesthesia induction, throughout the maintenance phase, until full recovery (approximately up to 4 hours).
Modified Observer's Assessment of Alertness/Sedation (MOAA/S) Score
The MOAA/S scale is a categorical measure used to assess the depth of sedation/anesthesia. Scores range from 0 (No response to painful stimulus) to 5 (Responds readily to name spoken in normal tone). This metric will be used as a pharmacodynamic endpoint to construct a categorical PK/PD model (e.g., proportional odds model) relating ciprofol concentration to clinical sedation depth.
Measured: Induction phase (every minute until loss of consciousness); Maintenance phase; and Post-operative phase (every 3 minutes in PACU until score returns to 5), up to approximately 4 hours.
Secondary outcomes (2)
Mean Arterial Pressure (MAP)
Evaluation of hemodynamic stability by measuring the absolute value of Mean Arterial Pressure. Reported in millimeters of mercury (mmHg).
Measured: Continuously measured during the induction, maintenance (intra-operative), and recovery phase (up to 2 hours post-infusion).
Heart Rate
Evaluation of hemodynamic stability by measuring the absolute value of Heart Rate. Reported in beats per minute (bpm).
Measured: Continuously measured during the induction, maintenance (intra-operative), and recovery phase (up to 2 hours post-infusion).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Dec 2025
- Study start28 Oct 2025
- Primary completionNov 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hip Fractures (ICD-10 72.01-72.2)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shanghai Geriatric Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Xue Zhang, Shanghai Geriatric Medical Center
- Investigators
- Xue Zhang, Principal investigator, Shanghai Geriatric Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07301242
- Sponsor's protocol ID
- ZCLY2025-021
- Status last verified
- Nov 2025
- First submitted
- 19 Nov 2025
- Last updated
- 24 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Population Pharmacokinetic/Pharmacodynamic Modeling of Ciprofol in Elderly Patients Undergoing Orthopedic Limb Surgery
- ClinicalTrials.gov ID
- NCT07301242
- Acronym / sponsor ID
- ZCLY2025-021
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Shanghai Geriatric Medical CenterUniversity, hospital or other
- Study start
- 28 Oct 2025 (actual)
- Primary completion
- Nov 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 24 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to learn how the anesthetic drug ciprofol works in older adults who are having limb surgery under general anesthesia at Shanghai Geriatric Medical Center. The study will help researchers build a population model to better understand how the drug moves through the body (PK) and how it affects patients (PD). This model may help doctors use a Target-Controlled Infusion (TCI) system to adjust the drug dose more precisely.
The main question it aims to answer is: Does ciprofol work safely and effectively in older adults during orthopedic surgery?
Participants already receiving ciprofol as part of their regular anesthesia care will:
- Provide blood samples at different time points during and after surgery.
- Have their vital signs and anesthesia-related data recorded before, during, and after surgery.
- Be monitored for side effects and recovery indicators such as the Aldrete score and signs of postoperative delirium.
Researchers will use this information to:
- Build and test a population PK/PD model for ciprofol.
- Simulate recommended TCI dosing plans.
- Explore how individual responses to ciprofol relate to recovery and safety outcomes.
This study may help improve anesthesia care for elder adults by making drug dosing safer and more effective.
Detailed description
Elderly patients undergoing orthopedic limb surgery represent a growing population with unique perioperative challenges. Age-related physiological changes-including reduced hepatic and renal function, altered body composition, and decreased cardiac output-significantly affect the pharmacokinetics (PK) and pharmacodynamics (PD) of anesthetic drugs. These changes increase the difficulty of maintaining adequate anesthesia depth and hemodynamic stability.
Ciprofol, a novel intravenous anesthetic, has shown promising efficacy and safety in clinical practice. However, existing PK/PD models are largely derived from healthy volunteers or younger patients, and cannot adequately predict drug behavior in elderly orthopedic patients who often present with comorbidities and heightened surgical stress. This gap may lead to risks such as drug accumulation and circulatory depression, or insufficient dosing and intraoperative awareness.
This single-center, observational, prospective study at Shanghai Geriatric Medical Center aims to construct and validate a population PK/PD model of ciprofol specifically for elderly patients undergoing orthopedic limb surgery. The model will support precise control of effect-site concentration via Target-Controlled Infusion (TCI) systems, enabling individualized anesthesia management.
Study Objectives 1.Primary Objective: To develop and validate a population PK/PD model of ciprofol tailored to elderly orthopedic patients, and to evaluate its accuracy in predicting effect-site concentrations.
2.Secondary Objectives:
- To simulate recommended TCI dosing regimens based on the new model and compare them with current drug label recommendations, assessing clinical value and optimization potential.
- To evaluate the anesthetic efficacy and safety of ciprofol in this patient population.
3.Exploratory Objectives: To investigate the influence of covariates (e.g., age, sex, BMI, hepatic and renal function) on PK/PD parameters, and to explore correlations between individual PK/PD parameters and recovery outcomes such as Aldrete score and postoperative delirium incidence.
Study Design
1.Type: Single-center, observational, biosample-utilization study. 2.Population: 45 elderly patients (≥65 years, ASA I-III) scheduled for elective orthopedic limb surgery under general anesthesia.
3.Procedures:
- Collection of perioperative clinical data (vital signs, BIS monitoring, anesthesia-related indicators).
- Serial blood sampling at predefined time points for plasma concentration measurement.
- Monitoring of anesthetic efficacy (induction success, BIS values, recovery times) and safety endpoints (hypotension, bradycardia, hypoxemia, injection pain).
4.Endpoints:
- Primary Endpoint: Accuracy of the population PK/PD model in predicting effect-site concentrations.
- Secondary Endpoints: Differences between model-recommended dosing and label-based dosing; incidence of ciprofol-related adverse events; anesthetic efficacy indicators.
- Exploratory Endpoints: Covariate effects on PK/PD parameters; correlation of PK/PD parameters with Aldrete score recovery and postoperative delirium.
Data Management and Analysis All perioperative data will be recorded and stored electronically, with double-entry verification and query resolution procedures to ensure accuracy. PK/PD modeling will be performed using nonlinear mixed-effects modeling (NONMEM). Model evaluation will include goodness-of-fit plots, visual predictive checks, and bootstrap validation. Simulations will be conducted to compare TCI dosing regimens derived from the new model with standard recommendations.
Expected Significance This study will fill an important gap in anesthetic pharmacology by providing a validated PK/PD model of ciprofol for elderly orthopedic patients. The findings are expected to improve perioperative anesthesia management, enhance patient safety, and support individualized dosing strategies in clinical practice.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Elderly Orthopedic Limb Surgery Cohort | – | Drug: CiprofolInclusion Criteria: Age ≥65 years; BMI 18-30 kg/m²; ASA physical status classification I-III; Scheduled for elective orthopedic limb surgery under general anesthesia; Expected duration of surgery >30 minutes; Willing to participate and able to provide written informed consent. Exclusion Criteria: Known allergy to ciprofol or related medications, or any contraindication to their use; Preoperative cognitive impairment (Mini-Cog score <3); History of severe cerebrovascular disease or related complications; History of neuromuscular system diseases or psychiatric disorders; History of sedative medication use; History of alcohol abuse or substance use disorder; Bradycardia (heart rate <60 beats per minute); Hypotension (mean arterial pressure <55 mmHg); QT interval prolongation; Uncooperative or unable to communicate effectively. |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- Elderly patients undergoing orthopedic limb surgery
Key inclusion criteria (6 listed)
- Age ≥65 years;
- BMI: 18-30 kg/m²;
- ASA physical status classification I-III;
- Scheduled for elective orthopedic limb surgery under general anesthesia;
- Expected duration of surgery >30 minutes;
Key exclusion criteria (10 listed)
- Known allergy to ciprofol or related medications, or any contraindication to their use;
- Preoperative cognitive impairment;
- History of severe cerebrovascular disease or related complications;
- History of neuromuscular system diseases or psychiatric disorders;
- History of sedative medication use;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CiprofolAlso: Cipepofol, SishuningCiprofol is used as an intravenous anesthetic agent for sedation and anesthesia induction/maintenance in elderly patients undergoing elective orthopedic limb surgery. In this observational study, ciprofol is administered according to standard clinical practices, and data on its pharmacokinetics, pharmacodynamics, safety, and effectiveness in this specific population will be collected. | Drug | Elderly Orthopedic Limb Surgery Cohort |
Primary outcome
Plasma Concentration of Ciprofol
Time frame: From the start of drug administration to 24 hours after the end of drug administration.
Arterial or venous blood samples (1 mL each) will be collected to measure the plasma concentration of ciprofol using liquid chromatography - mass spectrometry. These concentration data points will be used to construct the population pharmacokinetic model. Reported in ng/mL.
Bispectral Index (BIS) Value
Time frame: Continuously monitored from the start of anesthesia induction, throughout the maintenance phase, until full recovery (approximately up to 4 hours).
The BIS value is a non-invasive measure of the level of consciousness/depth of anesthesia, ranging from 0 (isoelectric EEG) to 100 (awake). It is used as the pharmacodynamic metric for modeling.
Modified Observer's Assessment of Alertness/Sedation (MOAA/S) Score
Time frame: Induction phase (every minute until loss of consciousness); Maintenance phase; and Post-operative phase (every 3 minutes in PACU until score returns to 5), up to approximately 4 hours.
The MOAA/S scale is a categorical measure used to assess the depth of sedation/anesthesia. Scores range from 0 (No response to painful stimulus) to 5 (Responds readily to name spoken in normal tone). This metric will be used as a pharmacodynamic endpoint to construct a categorical PK/PD model (e.g., proportional odds model) relating ciprofol concentration to clinical sedation depth.
2 secondary outcomes
Mean Arterial Pressure (MAP)
Time frame: Continuously measured during the induction, maintenance (intra-operative), and recovery phase (up to 2 hours post-infusion).
Heart Rate
Time frame: Continuously measured during the induction, maintenance (intra-operative), and recovery phase (up to 2 hours post-infusion).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Dec 2025.
- Individual participant dataSharing planned: No
Related trials for Hip Fractures (ICD-10 72.01-72.2)
Not yet recruitingPhase 4
Suzetrigine (Journavx) as Multimodal Therapy for Pain Management in Adults Undergoing Surgery for Hip Fracture
Hip Fractures (ICD-10 72.01-72.2), Post Operative Analgesia
Not yet recruitingObservational study
Improving Shared DECISion-making in oldEr Hip Fracture Patients Living With Frailty
Hip Fractures (i.e. Femoral Neck or Intertrochanteric Hip Fractures), Hip Fractures (ICD-10 72.01-72.2)
RecruitingObservational study
Mobility and Activity of Daily Living Outcomes After a Hip Fracture.
Hip Fractures (ICD-10 72.01-72.2)
Recruiting
Pre- and Postoperative Chest Therapy With Positive Expiratory Pressure (PEP) to Prevent Hospital-acquired Pneumonia
Hip Fractures (ICD-10 72.01-72.2)
Not yet recruiting
Frailty Intervention in Postoperative Hip Fracture Inpatients
Hip Fractures (ICD-10 72.01-72.2), Frailty at Older Adults
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Xue Zhang principal investigator
Shanghai Geriatric Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hip Fractures (ICD-10 72.01-72.2) and Osteoarthritis, Knee and Hip, run by Shanghai Geriatric Medical Center at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 24 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Xue Zhang (02164175590, zx02190554@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Plasma Concentration of Ciprofol (time frame: From the start of drug administration to 24 hours after the end of drug administration.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Dec 2025.